Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
Bachli
Esther B
EB
Vavricka
Stephan R
SR
Walter
Roland B
RB
Leschinger
Monika I
MI
Maggiorini
Marco
M
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011695:IgA Vasculitis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D007249:Inflammation; D008297:Male; D008589:Meningococcal Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012720:Severity of Illness Index; D012772:Shock, Septic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated